THE IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: A CAUSE OF DEATH IN PERSONS ON ANTIRETROVIRAL THERAPY?

REFERENCES

• Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitu-tion inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008; 68: 191–208.
   PubMed Web of Science ®Google Scholar
• Lorent N, Conesa-Botella A, Colebunders R. The immune reconstitution inflam-matory syndrome and antiretroviral therapy. Br J Hosp Med (Land) 2010; 71:691–697.
   Web of Science ®Google Scholar
• Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, van der Loeff MS, Reiss p, Lynen L, Janoff EN, Gilks C, Colebunders R. Tuberculosis-associated immune reconstitu-tion inflammatory syndrome: case definitions for use in resource-limited set-tings. Lancet Infect Dis 2008; 8:516–523.
   PubMed Web of Science ®Google Scholar
• Haddow U, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10(11): 791–802.
   PubMed Web of Science ®Google Scholar
• Grant PM, Komarow L, Andersen J, Sereti I, Pahwa S. Lederman MM et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 2010; 5(7): e11416.
   PubMed Web of Science ®Google Scholar
• Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune recon-stitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10(4): 251–261.
   PubMed Web of Science ®Google Scholar
• Mateen FJ, Nath A. Central nervous system-immune reconstitution inflamma-tory syndrome in resource-limited settings: current burden and future needs. AIDS 2012; 26:1851–1855.
   Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases/National Institutes of Health. HIV treatment study in pateints with cryptococcal meningitis ends enrollment early. NIAID/NIH Bulletin 2012; accesible on: http://www.niaid.nih.gov/news/newsreleases/2012/Pages/COAT.aspx
   Google Scholar
• Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011; 365(16): 1492–1501.
   PubMed Web of Science ®Google Scholar
• Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365(16): 1471–1481.
   PubMed Web of Science ®Google Scholar
• Marais S, Wilkinson RI, Pepper DJ, Meintjes G. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV /AIDS Rep 2009; 6(3): 162–171.
   PubMedGoogle Scholar
• Meintjes G, Wilkinson RI, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24(15): 2381–2390.
   PubMed Web of Science ®Google Scholar
• Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and inva-sive disease in AIDS: review of 342 cases. Chest 1998; 114(1): 251–262.
   PubMed Web of Science ®Google Scholar
• Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011; 9:415–430.
   PubMed Web of Science ®Google Scholar
• Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. CID 2008: 47: e83–e85.
   Web of Science ®Google Scholar
• Brunel A, Reynes J, Tuaillon E, et al. Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. AIDS 2012; 26(16): 2110–2112.
   PubMed Web of Science ®Google Scholar
• Hardwick C, White D, Morris E, Monteiro EF, Breen RA, Lipman M. Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 2006; 82: 513–514.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Scriven J, Marais S. Management of the Immune Reconstitution Inflammatory Syndrome. Curr HIV/AIDS Rep 2012; 9: 238–250.
   PubMed Web of Science ®Google Scholar
• Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum crypto-coccal antigen screening to prevent deaths among HIV-infected persons with a CD4 + cell count < or =100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010 15; 51: 448–455.
   Google Scholar